![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
LEP has formulated a line of products including CANNAVERA™, a family of topical pain relief products currently pending for over-the-counter (OTC) registration with the FDA.
Lead Product(s): Cannabis Sativa,Eugenia Caryophyllus Flower Oil,Rosmarinus Officinalis Leaf Extract
Therapeutic Area: Neurology Product Name: Cannavera
Highest Development Status: Approved Product Type: Small molecule
Recipient: Edge Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 12, 2021